Effect of hypertonic saline combined with dexmedetomidine on levels of neuroinflammatory factors in patients with craniocerebral injury

doi:10.3760/cma.j.issn.1007-1245.2023.22.031

Abstract

Abstract:

Objective　To investigate the inhibitory effects and therapeutic efficacy of 3% hypertonic saline combined with dexmedetomidine on the levels of serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), neuron-specific enolase (NSE), and central nervous system-specific protein (S100B) in patients with severe craniocerebral injury, and to provide new insights and methods for the treatment of patients with severe craniocerebral injury. Methods　The prospective study selected 58 patients with craniocerebral injury admitted to Department of Neurosurgery, Jieyang People's Hospital from September 2022 to August 2023 as the study objects. The patients were randomly divided into a control group and an observation group by the single blind method. The control group took mannitol and other sedative and analgesic drugs; in addition, the observation group took 3% hypertonic saline and dexmedetomidine. The serum levels of IL-6, TNF-α, NSE, and S100B were measured 12 (T₁), 24 (T₂), 48 (T₃), and 72 h (T₄) after injury. The data were compared between the two groups by t and χ² tests. Results　The serum levels of IL-6, TNF-α, NSE, and S100B at T₂, T₃, and T₄ in the observation group were (276.11±18.64) ng/L, (165.07±15.32) ng/L, and (126.07±16.15) ng/L, (1.27±0.21) ng/L, (1.22±0.25) ng/L, and (0.78±0.15) ng/L, (16.74±3.51) μg/L, (19.07±4.91) μg/L, and (14.97±2.21) μg/L, and (0.47±0.15) μg/L, (0.56±0.23) μg/L, and (0.32±0.16) μg/L, and those in the control group were (315.23±19.54) ng/L, (199.05±16.16) ng/L, and (141.02±17.98) ng/L, (1.47±0.25) ng/L, (1.45±0.22) ng/L, and (0.91±0.19) ng/L, (20.17±3.21) μg/L, (24.17±5.61) μg/L, and (17.06±2.98) μg/L, and (0.67±0.28) μg/L, (0.87±0.32) μg/L, and (0.47±0.13) μg/L, the difference between the two groups was statistically significant (all P<0.05). Conclusion　Three percent hypertonic saline combined with dexmedetomidine can inhibit the expression of neuroinflammatory factors in patients with severe craniocerebral injury and alleviate secondary brain injury.

Key words:

Severe craniocerebral injury, Hypertonic saline, Dexmedetomidine, Interleukin-6, Tumor necrosis factor-alpha, Neuron-specific enolase, Central nervous system-specific protein

摘要：

目的　本研究探讨3%高渗盐水联合右美托咪定对重型颅脑损伤患者血清白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、神经元特异性烯醇化酶（NSE）及中枢神经特异蛋白（S100B）水平的抑制作用，为重型颅脑损伤患者的治疗提供了新的思路和方法。方法　前瞻性研究选取2022年9月至2023年8月揭阳市人民医院神经外科收治的58例颅脑损伤患者为研究对象，采用随机、单盲法分为对照组和观察组。对照组采用甘露醇与其他镇静镇痛药物进行基础治疗，观察组在对照组的基础上加用3%高渗生理盐水及右美托咪定进行强化治疗。在伤后12 h（T₁）、24 h（T₂）、48 h（T₃）和72 h（T₄）测定血清IL-6、TNF-α、NSE及S100B水平。组间比较采用t检验、χ²检验。结果　观察组患者在T₂、T₃和T₄时刻的血清IL-6分别为（276.11±18.64）ng/L、（165.07±15.32）ng/L、（126.07±16.15）ng/L，TNF-α分别为（1.27±0.21）ng/L、（1.22±0.25）ng/L、（0.78±0.15）ng/L，NSE分别为（16.74±3.51）μg/L、（19.07±4.91）μg/L、（14.97±2.21）μg/L，S100B分别为（0.47±0.15）μg/L、（0.56±0.23）μg/L、（0.32±0.16）μg/L；对照组患者在T₂、T₃和T₄时刻的血清IL-6分别为（315.23±19.54）ng/L、（199.05±16.16）ng/L、（141.02±17.98）ng/L，TNF-α分别为（1.47±0.25）ng/L、（1.45±0.22）ng/L、（0.91±0.19）ng/L，NSE分别为（20.17±3.21）μg/L、（24.17±5.61）μg/L、（17.06±2.98）μg/L，S100B分别为（0.67±0.28）μg/L、（0.87±0.32）μg/L、（0.47±0.13）μg/L。两组比较差异均有统计学意义（均P<0.05）。结论　3%高渗盐水联合右美托咪定可抑制重型颅脑损伤患者神经炎症因子水平的表达，减轻继发性脑损伤。

关键词:

重型颅脑损伤, 高渗盐水, 右美托咪定, 白细胞介素-6, 肿瘤坏死因子α, 神经元特异性烯醇化酶, 中枢神经特异蛋白

Hu Xuwei, Li Zuoshi, Liu Guoyuan.

Effect of hypertonic saline combined with dexmedetomidine on levels of neuroinflammatory factors in patients with craniocerebral injury [J]. International Medicine and Health Guidance News, 2023, 29(22): 3280-3283.

胡旭威李作士刘国元.

高渗盐水联合右美托咪定对重型颅脑损伤患者神经炎症因子水平的影响 [J]. 国际医药卫生导报, 2023, 29(22): 3280-3283.

References

[1] 张金庆,刘文静.重型颅脑损伤患者照顾者负担与社会支持的相关性研究[J].护理管理杂志,2012,12(2):83-84.DOI:10.3969/j.issn.1671-315X.2012.02.003.
[2] Khatri N, Sumadhura B, Kumar S, et al. The complexity of secondary cascade consequent to traumatic brain injury: pathobiology and potential treatments[J]. Curr Neuropharmacol, 2021,19(11):1984-2011. DOI: 10.2174/1570159X19666210215123914.
[3] 闵小彬,郭志刚.连续应用3%高渗盐水对于治疗重型颅脑损伤后脑水肿的临床效果[J].吉林医学,2022,43(4):994-996.DOI:10.3969/j.issn.1004-0412.2022.04.049.
[4] 吴婷,葛志军,朱敏敏,等.不同剂量右美托咪定静脉维持对重型颅脑损伤患者术后生命体征、免疫功能和血清神经细胞因子的影响[J].现代生物医学进展,2022,22(6):1131-1136.DOI:10.13241/j.cnki.pmb.2022.06.028.
[5] Jacquens A, Needham EJ, Zanier ER, et al. Neuro-inflammation modulation and post-traumatic brain injury lesions: from bench to bed-side[J]. Int J Mol Sci, 2022,23(19):11193. DOI: 10.3390/ijms231911193.
[6] Rodney T, Osier N, Gill J. Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: a review[J]. Cytokine, 2018,110:248-256. DOI: 10.1016/j.cyto.2018.01.012.
[7] 钱晓波,季东凯,倪海波.重型颅脑损伤患者血清NSE及CRP检测及其意义[J].系统医学,2022,7(13):19-22.DOI:10.19368/j.cnki.2096-1782.2022.13.019.
[8] Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury[J]. Expert Rev Mol Diagn, 2018,18(2):165-180. DOI: 10.1080/14737159.2018.1428089.
[9] Bychkov R, Juhaszova M, Calvo-Rubio Barrera M, et al. The heart's pacemaker mimics brain cytoarchitecture and function: novel interstitial cells expose complexity of the SAN[J]. JACC Clin Electrophysiol, 2022,8(10):1191-1215. DOI: 10.1016/j.jacep.2022.07.003.
[10] 袁晓帆,王建红,王多姿,等.神经元特异性烯醇化酶、S100 B蛋白在脑缺血损伤中的研究进展[J].实用医院临床杂志,2019,16(6):237-239.DOI:10.3969/j.issn.1672-6170. 2019.06.076.
[11] Amirshahrokhi K, Niapour A. Methylsulfonylmethane protects against ethanol-induced brain injury in mice through the inhibition of oxidative stress, proinflammatory mediators and apoptotic cell death[J]. Int Immunopharmacol, 2022,106:108638. DOI: 10.1016/j.intimp.2022.108638.
[12] Shlosberg D, Benifla M, Kaufer D, et al. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury[J]. Nat Rev Neurol, 2010,6(7):393-403. DOI: 10.1038/nrneurol.2010.74.
[13] 马志海.炎症反应在脑出血后继发性脑损伤中作用机制的研究进展[J].中国临床神经外科杂志,2020,25(2):124-126.DOI:10.13798/j.issn.1009-153X.2020.02.022.
[14] 胡辉平,张昊奇,李奕霖,等.高渗盐水对比甘露醇治疗颅内压升高患者的疗效和安全性:基于随机对照试验的Meta分析的伞形Meta分析[J].中国医院药学杂志,2022,42(16):1685-1691,1708.DOI:10.13286/j.1001-5213.2022.16.11.
[15] 中华医学会神经外科学分会,中国神经外科重症管理协作组,中国神经外科转化与循证医学协作组,等.高渗盐水治疗脑水肿及颅内高压的专家共识[J].中华医学杂志,2022,102(17):1258-1266.DOI:10.3760/cma.j.cn112137- 20211114- 02538.
[16] 陈胜龙.高渗盐水通过EGFR信号通路减轻血脑屏障内皮细胞缺血缺氧损伤的实验研究[D].广州:南方医科大学,2017.
[17] 张俊,张恒柱,李育平,等.高渗盐水治疗脑损伤性颅高压有效性与安全性的Meta分析[J].临床神经外科杂志,2022,19(4):458-464.DOI:10.3969/j.issn.1672-7770. 2022.04.020.
[18] Jiang L, Hu M, Lu Y, et al. The protective effects of dexmedetomidine on ischemic brain injury: a meta-analysis[J]. J Clin Anesth, 2017,40:25-32. DOI: 10.1016/j.jclinane.2017.04.003.
[19] Sun D, Wang J, Liu X, et al. Dexmedetomidine attenuates endoplasmic reticulum stress-induced apoptosis and improves neuronal function after traumatic brain injury in mice[J]. Brain Res, 2020,1732:146682. DOI: 10.1016/j.brainres.2020.146682.
[20] 邓晰明,邹琪,段立彬,等.右美托咪定对重型颅脑外伤术后脑氧代谢的影响[J].中山大学学报(医学科学版),2016,37(4):630-636.DOI:10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2016.0107.
[21] Tian Y, Xiao X, Zhu X, et al. Neuroprotective effects of dexmedetomidine combined with goal-directed haemodynamic therapy for patients undergoing cranial surgery[J]. Eur J Anaesthesiol, 2023,40(1):63. DOI: 10.1097/EJA.0000000000001714.